Subgroup analyses demonstrated mCAPOX/mCAPIRI plus bevacizumab had similar PFS benefits in patients with different ages, sex, performance status, prior treatments, tumor locations or metastases, BRAF mutations, or with conversion therapy or not. Here, BRAF is linked to neoplasm.